Galapagos Targets Liver Fibrosis With Evotec Deal

Belgium’s Galapagos adds another potential fibrosis drug to its growing pipeline of compounds in a therapeutic area that is also attracting attention from a number of other companies.  

Liver
Liver fibrosis has been targeted by a number of pharma companies • Source: Shutterstock

Mechelen, Belgium-based Galapagos NV is extending its interest in fibrosis R&D with an early-stage collaboration with Evotec AG involving liver and other organ fibrosis, the second deal finalized by the former this year to target fibrotic diseases.

Under the latest fibrosis collaboration, announced Feb

More from Clinical Trials

More from R&D